News and Trends 16 Feb 2022 Startup Bags €50M Series A to Smash Gene Therapy Vector Limits After closing Spain’s largest biopharma Series A round, the company SpliceBio has set its foundations in the gene therapy field and joins the push to deliver bigger therapeutic genes into patients. SpliceBio was founded in 2012 to tinker with a type of protein called inteins, which can stick peptides together to form new proteins. The […] February 16, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jan 2022 Two Gene Therapy Players Launch IPOs on Stormy Stock Market After a drought of more than a year, the European gene therapy sector saw initial public offerings from Genenta Science and Genflow Biosciences. The firms aim to shine as biotech stocks elsewhere perform poorly. Until recently, European gene therapy companies were going through a dry spell in terms of launching initial public offerings (IPO). The […] January 21, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jan 2022 Europe Trailed US Despite Record Gene and Cell Therapy Funding in 2021 Cell and gene therapy developers globally raised an all-time annual record in 2021. However, European firms missed out on the funding growth. Companies around the world developing cell and gene therapies raised €20.1B ($23.1B) over 2021, said the advanced therapy advocacy organization the Alliance for Regenerative Medicine (ARM) in a briefing this week. This bumper […] January 14, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Dec 2021 The Biggest European Biotech News of 2021 In spite of the challenges posed by the Covid-19 pandemic, the European biotech industry has emerged stronger than ever this year. These were the key moments for the sector in 2021. The year 2021 has seen skyrocketing fortunes for many European biotech players. Investment firms, for instance, raised far more funding than in 2020, which […] December 22, 2021 - 10 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Infographics by Merck 15 Nov 2021 Gene therapy: Making Rare Disease Therapies Less Rare While individually uncommon, rare diseases collectively impact the lives of over 300 million people worldwide. Many rare conditions are chronic, progressive, and life-threatening with limited treatment options available. Advances in gene therapy provide hope to actual cures and could revolutionize treatment prospects for patients with rare genetic diseases. This infographic shows how we can unlock […] November 15, 2021 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2021 Skilled Labor Shortages Impact Cell And Gene Therapy Manufacturing Despite vast amounts of funding entering the cell and gene therapy field, the manufacture of these therapies is held back by skill shortages. Increasing training programs and automation could form the solution. The cell and gene therapy fields enjoyed their best-ever funding yield in the first half of 2021, with €12.2B ($14.1B) netted globally. However, […] November 4, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Sponsored by OXGENE 26 Oct 2021 Plasmids: How to Solve a Bottleneck in Scalable Gene Therapy Manufacturing? As gene therapies become increasingly successful, companies are in a competitive race to deliver manufacturing technologies that can streamline large-scale production at reduced costs and faster turnaround times. However, plasmids, the building blocks of viral vectors, remain a bottleneck in gene therapy manufacturing. Two companies have united to provide exciting alternatives. With over 2,400 gene […] October 26, 2021 - 7 minutesmins - By Letícia Manosso Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2021 Non-Viral Gene Therapies Get €51M Boost, Though Challenges Remain Although most gene therapy still relies on non-infectious viral vectors for delivery, a recent venture financing round for the Swiss company Anjarium Biosciences has shone the spotlight on alternative vectors, including lipid nanoparticles and electric pulses. Last month, Anjarium Biosciences raised €51M (CHF55.5M) in a Series A financing round to advance its gene delivery system […] October 4, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2021 Sofinnova Taps into Italian Gene Therapy with Three Seed Financings The French investor Sofinnova Partners has injected a total of €6M into three Italian gene therapy companies, cementing Italy’s reputation as a European center for cell and gene therapies. Last month, the venture capitalist Sofinnova Partners used its Telethon fund to inject cash into AAVantgarde Bio, Borea Therapeutics, and Alia Therapeutics. The three firms will […] July 12, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jul 2021 The Top European Biotech Funding Rounds in June While oncology and psychedelics dominated European biotech’s biggest funding rounds last month, startup seed financing focused more on gene therapy and drug discovery. Last month saw some momentous events for Europe’s biotech heavyweights. GSK paid an impressive €524M ($625M) upfront to co-develop an immuno-oncology candidate with iTeos Therapeutics in Belgium. Meanwhile, the German antibody drug […] July 8, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2021 Delayed IPOs and Market Drops Batter Biotech Stocks Stock markets worldwide have experienced painful instability in the last few months. As a result, the European biotech market has seen stock prices falling and IPOs postponed. The Covid-19 pandemic was a major disruption for stock markets across the globe at the start of 2020. However, markets like Euronext and the tech-focused Nasdaq rallied and […] May 25, 2021 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 May 2021 Bluebird Bio Withdrawal Raises Gene Therapy Doubts in Europe Last month, the US firm bluebird bio abandoned the sale of its gene therapy Zynteglo in Germany after a pricing dispute with health authorities — a blow that could have repercussions for the rollout of other gene therapies in Europe. Zynteglo was approved in the EU in 2019 as the first-ever gene therapy for the […] May 4, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email